, Volume 17, Issue 4, pp 320–326 | Cite as

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

  • M. Boscaro
  • J. Bertherat
  • J. Findling
  • M. Fleseriu
  • A. B. Atkinson
  • S. Petersenn
  • J. Schopohl
  • P. Snyder
  • G. Hughes
  • A. Trovato
  • K. Hu
  • M. Maldonado
  • B. M. K. Biller
Open Access


In a previous 15-day, Phase II study of patients with de novo or persistent/recurrent Cushing’s disease (core study), treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76 % of patients and normalized UFC in 17 %. The objective of this study was to evaluate the efficacy and safety of extended treatment with pasireotide. This was a planned, open-ended, single-arm, multicenter extension study (primary endpoint: 6 months). Patients aged ≥18 years with Cushing’s disease who completed the core study could enter the extension if they achieved UFC normalization at core study end and/or obtained significant clinical benefit. Of the 38 patients who completed the core study, 19 entered the extension and 18 were included in the efficacy analyses (three responders, 11 reducers, four non-reducers in the core study). At data cut-off, median treatment duration in the extension was 9.7 months (range: 2 months to 4.8 years). At extension month 6, 56 % of the 18 patients had lower UFC than at core baseline and 22 % had normalized UFC. Of the four patients who remained on study drug at month 24, one had normalized UFC. Reductions in serum cortisol, plasma adrenocorticotropic hormone, body weight and diastolic blood pressure were observed. The most common adverse events were mild-to-moderate gastrointestinal disorders and hyperglycemia. Pasireotide offers a tumor-directed medical therapy that may be effective for the extended treatment of some patients with Cushing’s disease.


Pasireotide SOM230 Cushing’s disease Somatostatin analogue Clinical trial 


Cushing’s disease is the clinical consequence of chronic hypercortisolism caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma [1]. Patients with Cushing’s disease have 4.8-fold higher mortality than the general population [2] and a high level of cardiovascular, metabolic and osteoporotic comorbidities [2, 3, 4]. First-line treatment for patients with Cushing’s disease is transsphenoidal surgery, with remission rates of 65–90 % in patients with a microadenoma, if performed by an expert pituitary surgeon [1]. Second-line options include repeat surgery, radiotherapy, medical therapy and bilateral adrenalectomy [1]. However, lower success rates are seen after repeat surgery than after the initial surgery, and hypopituitarism is more common [1]. Hypopituitarism is also common after radiotherapy [5], whereas bilateral adrenalectomy results in permanent hypoadrenalism [1].

The most commonly used medical therapies are steroidogenesis inhibitors, none of which have been evaluated in large, prospective clinical trials. These agents are generally used off-label [1, 6]. Recently, pasireotide has been approved as a medical therapy for Cushing’s disease in the EU and US [7], and mifepristone is available to treat hyperglycemia associated with hypercortisolism in the US [8].

Corticotroph adenomas express multiple somatostatin receptor subtypes (sst), making somatostatin analogues a rational therapeutic option for patients with these tumors. Pasireotide is a multireceptor-targeted somatostatin analogue with high affinity for sst1, sst2 and sst3, and highest affinity for sst5 [9]. The receptor sst5 is present on most corticotroph adenomas [10]. In a 15-day, proof-of-concept, Phase II study in patients with de novo or persistent/recurrent Cushing’s disease, treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76 % (22/29) of patients and led to normal UFC levels in five patients (17 %) [11]. This paper presents results from the extension phase of the Phase II study and evaluates the long-term efficacy and safety of pasireotide in patients who chose to continue the medication.

Patients and methods


Patients with Cushing’s disease (aged ≥18 years) who had completed the 15-day, proof-of-concept, Phase II core study [11] were eligible to enter this extension phase if they had normal 24-h UFC levels at the end of the core study and/or, in the opinion of the investigator, obtained significant clinical benefit with pasireotide. Confirmation of Cushing’s disease was previously described in the core study [11]. Inclusion and exclusion criteria for the extension study are reported in the Supplementary Material.

This study was approved by the Independent Ethics Committee, Institutional Review Board or Research Ethics Board for each study center. The study was conducted according to the ethical principles of the Declaration of Helsinki. All patients provided written informed consent.

Study design

This open-ended, single-arm extension study (ClinicalTrials.gov NCT00171951) was a planned extension to the 15-day core study [11]. Patients who achieved normalized UFC levels at the end of the core study continued at a dose of 600 μg sc bid. If UFC levels increased, the pasireotide dose could be increased to 900 μg sc bid. The dose of pasireotide could be reduced by 150 μg per injection at any time if the investigator believed that a drug-related adverse event (AE) was present.

Patients were to be discontinued from the extension study if they failed to demonstrate ongoing treatment benefit, experienced an unacceptable AE (defined as drug-related toxicity of Common Terminology Criteria [CTCAE v3.0] [12] grade 3 or 4 that did not resolve to grade 1 within 24 h), experienced evidence of disease progression or received any other therapeutic intervention for Cushing’s disease (see Supplementary Material for further details).


The primary efficacy outcome was the proportion of patients with normalized UFC levels after 6 months of treatment (normal UFC range: 55–276 nmol/24 h; 20–100 μg/24 h). Secondary objectives included assessment of the safety and tolerability of multiple doses of pasireotide and trough plasma concentrations of pasireotide after chronic dosing.


Patients were classified as ‘UFC responders’ if their mean UFC level at month 6 was in the normal range; as ‘UFC reducers’ if their mean UFC level at month 6 was lower than that at core study baseline but not within normal limits; and as ‘UFC non-reducers’ if their mean UFC level at month 6 was equal to or higher than that at core study baseline or if the mean UFC level at month 6 was missing. Patients who discontinued prior to month 6 were classified as non-responders.

Blood samples for serum cortisol, plasma ACTH and pharmacokinetic assessments were collected before the morning pasireotide dose on study visit days. UFC assays were conducted in two central laboratories, one in Europe and the other in the US. Serum cortisol and plasma ACTH assays were assessed centrally by one laboratory (see Supplementary Material for further details).

Safety was assessed by recording all AEs, as well as by regular monitoring of vital signs, physical condition, body weight, hematology and blood chemistry. HbA1c levels were recorded at extension baseline and then every 16 weeks. HbA1c categories were: <upper limit of normal (ULN; normal defined as <5.7 %), between the ULN and 7 %, between 7 and 9 %, and over 9 %.

Statistical methods

Summary statistics were provided for the primary and secondary endpoints. No formal statistical comparisons were performed for this study because of the small sample size. The analysis populations were defined as follows: the intention-to-treat (ITT) and safety populations consisted of patients who received at least one pasireotide dose in the extension period. The primary efficacy population consisted of those ITT patients whose mean UFC at core baseline, based on at least two UFC samples, was >ULN.


Of 38 patients who completed 15 days’ pasireotide therapy, 19 entered this extension phase, 17 women and two men, all Caucasian, mean age 43 years (range 22–73, standard deviation [SD]: 11.6). One patient had normal UFC levels on entry into the core study and was therefore excluded from the primary efficacy analysis. Three patients who entered the extension study had normal UFC levels at the end of the core study. Between completing the core study and entering the extension, 10 patients experienced a treatment interval. During this interim period, patients did not receive pasireotide (range of interval: 6–367 days). Information on other treatments for Cushing’s disease was not collected during the treatment intervals (see Supplementary Material for further details).

All patients entered the extension phase on a dose of 600 μg sc bid. At data cut-off, the treatment duration ranged from 2 months to 4.8 years and the median treatment duration was 9.7 months at that time. Three patients were continuing to receive treatment at the time of the data cut-off. Overall, 16 patients discontinued treatment during the extension study. The main reasons for discontinuation were to start new therapy for Cushing’s disease (five [26.3 %]), withdrawal of consent (three [15.8 %]), unsatisfactory therapeutic effect after 5–10 months (three [15.8 %]), AE (one [5.3 %]: new-onset type 2 diabetes mellitus), and abnormal laboratory value (two [10.5 %]: one increased HbA1c and glucose and one elevated UFC). Seven patients discontinued treatment prior to month 6.

Effects of pasireotide therapy at month 6

UFC levels at month 6

Of the 18 patients included in the primary efficacy analysis, four had normal UFC levels at month 6 (responders, 22.2 %; 95 % confidence interval [CI] 6.4–47.6). Six patients (33.3 %) achieved a reduction in mean UFC, but not to within normal range (reducers). One patient had a mean UFC level greater than at baseline and was classified as a non-reducer; the remaining seven patients were also considered to be non-reducers because they discontinued treatment prior to month 6.

In the 18 patients included in the primary efficacy analyses, mean UFC (± SD) decreased from core baseline by −802 ± 819 nmol/24 h to month 6 of the extension (Table 1).
Table 1

Change in UFC, serum cortisol and plasma ACTH from core baseline to day 15 and months 6, 12 and 24


Core baseline

Day 15

Month 6

Month 12

Month 24

UFC (nmol/24 h)

[μg/24 h]







Mean ± SD

1,220 ± 753

[442 ± 273]

522 ± 302

[189 ± 109]

421 ± 340

[153 ± 123]

398 ± 220

[144 ± 80]

514 ± 456

[186 ± 165]


291, 2,760

[105, 1,000]

158, 1,133

[57.3, 411]

159, 1,267

[58.0, 459.1]

198, 707

[72, 256]

80, 1,141

[29.0, 413]

Mean change from core baseline ± SD

−711 ± 741b

[−258 ± 269]

−802 ± 819c

[−291 ± 297]

−1,202 ± 1,084

[−436 ± 393]

−1,241 ± 926

[−450 ± 336]



−2,340, 367

[−848, 133]

−2,388, 34

[865, 12.3]

−2,367, −272

[−858, −99.0]

−2,236, −57

[−810, −20.7]

Serum cortisol (nmol/L)









724 ± 222

[26.2 ± 8.0]

698 ± 161

[25.3 ± 5.8]

559 ± 300

[20.3 ± 10.9]

685 ± 79.0

[24.8 ± 2.9]

628 ± 181

[22.8 ± 6.6]


442, 1,187

[16.0, 43.0]

414, 1,049

[15.0, 38.0]

193, 1,297

[7.0, 47.0]

580, 773

[21.0, 28.0]

414, 856

[15.0, 31.0]

Mean change from core baseline ± SD

−26.0 ± 125

[−0.9 ± 4.5]

−151 ± 309

[−5.5 ± 11.2]

−66.1 ± 302

[−2.4 ± 11.0]

−228 ± 283

[−8.3 ± 10.3]



−304, 138

[−11.0, 5.0]

−773, 221

[−28.0, 8.0]

−469, 303

[−17.0, 11.0]

−414, 194

[−15.0, 7.0]

Plasma ACTH (pmol/L)








Mean ± SD

13.7 ± 11.0

[62.3 ± 50.0]

12.4 ± 8.9

[56.4 ± 40.5]

9.6 ± 4.9

[43.2 ± 22.3]

9.8 ± 3.8

[44.5 ± 17.3]

12.0 ± 6.3

[54.5 ± 28.6]


2, 46

[9.1, 209]

4, 40

[18.2, 182]

4, 17

[18.2, 77.3]

4, 14

[18.2, 63.6]

4, 17

[18.2, 77.3]

Mean change from core baseline ± SD

−1.3 ± 7.1

[−5.9 ± 32.3]

−3.4 ± 9.4

[−15.5 ± 42.7]

−3.6 ± 15.2

[−16.4 ± 69.1]

−4.5 ± 8.3

[−20.5 ± 37.7]



−17, 16

[−77.3, 73.0]

−23, 10

[−104, 45.5]

−27, 12

[−122, 54.5]

−14, 5

[−63.6, 22.7]

Core baseline is considered as pre-dose on day 1. Normal range for UFC: 55–276 nmol/24 h (20–100 μg/24 h); normal range for serum cortisol: 221–690 nmol/L (8.0–25.0 μg/dL; 09:00 h measure); normal range for plasma ACTH: <10 pmol/L (<45.5 pg/mL). The mean change from baseline was calculated only in those patients with evaluable measurements at baseline and month 6

an is the number of patients in the primary efficacy population who have a mean UFC value at core baseline and at a particular visit

bn = 16

cn = 10

Serum cortisol and plasma ACTH levels at month 6

Consistent with the reduction in UFC levels, mean serum cortisol (±SD) and plasma ACTH levels decreased from core baseline by −151 ± 309 nmol/L and −3.4 ± 9.4 pmol/L, respectively, at month 6 (Table 1).

Ongoing effects of pasireotide therapy up to 24 months

The reductions in mean UFC persisted in the four patients who were on study drug at month 24 (Table 1). Of these four patients, three had >50 % reduction in mean UFC from core baseline. One patient had been a responder at the end of the core study. Despite variability in serum cortisol levels, there was an overall reduction in serum cortisol and plasma ACTH relative to core baseline that was maintained throughout the extension (Table 1). There was an overall reduction in body weight and diastolic blood pressure over time (Table 2). Clinical improvements were not limited to patients who achieved UFC control. The sample size was not large enough to assess the significance of these results.
Table 2

Change in vital signs from core baseline to day 15 and months 6, 12 and 24


Core baseline

Day 15

Month 6

Month 12

Month 24

Body weight (kg)







Mean ± SD (range)

81.7 ± 19.3

(58.8, 132.4)

80.1 ± 19.7

(56.5, 132.5)

74.3 ± 11.5

(46.0, 90.8)

73.1 ± 14.0

(49.0, 91.7)

71.9 ± 17.0

(48.3, 88.5)

Mean percentage change from core baseline ± SD (range)

−2.0 ± 4.1

(−15.5, 5.3)

−6.9 ± 9.5

(−25.1, 7.3)

−11.2 ± 10.8

(−23.8, 4.4)

−11.1 ± 12.3

(−20.8, 6.2)

Systolic blood pressure (mmHg)







Mean ± SD (range)

129.8 ± 13.7

(110, 155)

127.7 ± 11.4

(110, 146)

120.9 ± 8.9

(100, 131)

129.1 ± 10.9

(115, 145)

129.0 ± 16.4

(110, 145)

Mean percentage change from core baseline ± SD (range)

−1.1 ± 8.4

(−17.9, 13.3)

−2.6 ± 7.4

(−16.7, 8.7)

1.2 ± 8.6

(−10.2, 12.5)

−0.1 ± 15.0

(−12.9, 20.8)

Diastolic blood pressure (mmHg)







Mean ± SD (range)

85.5 ± 8.1

(70, 100)

81.7 ± 9.9

(60, 102)

77.6 ± 8.3

(60, 90)

74.9 ± 12.1

(53, 90)

79.3 ± 16.4

(60, 100)

Mean percentage change from core baseline ± SD (range)

−3.9 ± 12.3

(−25.0, 22.9)

−7.4 ± 8.4

(−25.0, 2.9)

−14.1 ± 11.7

(−36.1, 2.4)

−6.52 ± 19.2

(−25.0, 20.5)


Mean ± SD Ctrough levels at month 6 were 17.4 ± 11.6 and 19.1 ± 10.9 μg/L in UFC responders (n = 4) and reducers (n = 6), respectively, and 5.2 μg/L in non-reducers (n = 1). These values were higher than those at the end of the core study, when mean ± SD Ctrough levels were 7.0 ± 4.3 and 4.4 ± 1.1 μg/L in UFC responders and reducers, respectively, and 2.7 μg/L in non-reducers.

Safety and tolerability of pasireotide up to month 24

All patients experienced at least one AE during the study. With the exception of hyperglycemia, AEs were generally as expected and were mostly related to transient gastrointestinal discomfort (Table 3). One patient discontinued treatment because of an AE (new-onset type 2 diabetes mellitus). Thirteen patients reported a hyperglycemia-related adverse event: 11 patients had a reported AE of hyperglycemia, one patient had increased blood glucose, and one patient reported type 2 diabetes. Two patients had grade 4 AEs: one was increased γ-glutamyltransferase levels and the other was type 2 diabetes mellitus. Both events were suspected by the investigator to be related to study drug. No patients died during the study.
Table 3

Most frequently occurring adverse events (>5 patients) regardless of study-drug relationship

Adverse event

n (%)


13 (68.4)


12 (63.2)


11 (57.9)

Abdominal pain

9 (47.4)


7 (36.8)

Injection-site pain

6 (31.6)


5 (26.3)


5 (26.3)

Injection-site pruritus

5 (26.3)

At extension baseline, eight of the 19 patients had HbA1c values available, all of which were <ULN (extension baseline mean ± SD: 5.78 ± 0.51 %). HbA1c was not measured during the core study. Six patients had post-baseline HbA1c levels shifted to a higher category at some point during the extension and were treated with modification of diet or with antidiabetic medication, including metformin, glimepiride, exenatide, pioglitazone or insulin. Five of these six patients remained at a higher post-baseline HbA1c level at their last assessment.

All patients experienced an increase in fasting plasma glucose (FPG) level at some point during the extension study (see Supplementary Material). Of the 16 patients with normal FPG at extension baseline, FPG levels shifted to between 100 and <126 mg/dL (5.6 to <7.0 mmol/L) in six patients, between 126 and <200 mg/dL (7.0 to <11.1 mmol/L) in four patients and ≥200 mg/dL (≥11.1 mmol/L) in six patients at some point during the extension study. All patients had improved FPG levels at their last assessment.

Electrocardiogram intervals were generally within normal ranges during the study. One patient had a newly occurring QT of 450–480 ms, another patient had a newly occurring QTcB of 450–480 ms, and one patient had a QRS interval of >110 ms (not clinically significant).


The results of this study support the extended treatment with pasireotide in some patients with Cushing’s disease. After 6 months of therapy, 10 of 18 patients (56 %) achieved reduced UFC levels compared with core baseline, and four patients (22 %) had normalized UFC levels. Mean serum cortisol and plasma ACTH levels also decreased over this period, irrespective of whether UFC control was achieved. These pasireotide-induced reductions were maintained in four patients who were treated for over 24 months. These findings led to the initiation of a Phase III study of pasireotide in 162 patients with persistent/recurrent or de novo Cushing’s disease [13]. The Phase III study found that pasireotide treatment led to a rapid and sustained decrease in UFC levels. The UFC normalization rate at month 6 in the current study (22 %) and the Phase III study (20.4 %) was similar. Based on the findings from the Phase III study, pasireotide was approved in the EU and US for the treatment of patients with Cushing’s disease for whom surgery is not an option or who decline surgery. The current study shows that this response can be maintained for at least 24 months in some patients. In fact, a patient case from this study has illustrated long-term UFC control without escape or serious AEs during >7 years of treatment with pasireotide sc [14].

Long-term reductions in body weight and diastolic blood pressure were found in the current study, which in part may reflect the sustained reduction in cortisol levels and may attenuate the considerable morbidity observed in patients with Cushing’s disease [2, 3, 4]. While the sample size in the present study was not large enough to test the statistical significance of this result, significant improvements in clinical signs and symptoms were observed in the much larger Phase III study of pasireotide in Cushing’s disease [13, 15].

The results of the current study suggest that there may be a relationship between the plasma concentration of pasireotide and its effect on UFC levels. Interestingly, trough plasma concentrations of pasireotide were higher at month 6 than at the end of the core study. The reasons for this are unclear, and it is difficult to fully interpret this finding because of the small sample size.

The safety profile of pasireotide in this study is similar to that of previous pasireotide studies [11, 13]. In line with the safety profile of other somatostatin analogues, the most frequently occurring drug-related AEs are mild-to-moderate and transient gastrointestinal disturbances. The prevalence of hyperglycemia-related AEs in this study was higher than seen with other somatostatin analogues in other indications [16, 17, 18]. Patients with Cushing’s disease are predisposed to alterations in glucose homeostasis [19], and a higher prevalence of diabetes mellitus and glucose intolerance has been reported in patients with Cushing’s disease compared with the general population [20]. In the present study, none of the eight patients with available glycemic data had elevated HbA1c levels at extension baseline. However, the possibility of glucose intolerance could not be excluded in these patients. During the treatment period, hyperglycemia-related AEs were reported in 68 % of patients (13/19). Seven continued pasireotide treatment with concomitant treatment for hyperglycemia-related AEs, five continued with no medication for hyperglycemia and one patient discontinued. It is therefore important to monitor glucose levels during pasireotide treatment and initiate prompt medical intervention and close follow-up [21].

There are several limitations of this study that may have affected the findings, most notably the small number of patients who entered the extension period and who continued to receive pasireotide after 6 months. This limits the conclusions that can be drawn from some of the analyses, particularly of the pharmacokinetic data. In addition, HbA1c measurements were available for only 42 % of patients at baseline, which rendered the study less informative than planned with regard to the effects of pasireotide on glucose homeostasis. However, the results of the study are consistent with the much larger Phase III study of pasireotide [13].

In conclusion, pasireotide offers a tumor-directed medical therapy and may be effective for the long-term treatment of some patients with Cushing’s disease.



We thank Daniel Webber, Mudskipper Business Ltd, for medical editorial assistance with this manuscript. This study was funded by Novartis Pharma AG. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.

Conflict of interest

A.T., G.H. and K.H. are employees of Novartis. M.M. was an employee of Novartis during this study but is now employed by Boehringer Ingelheim. M.B. has no financial relationship or commercial interest. J.B. has been an investigator and consultant for Novartis, Ipsen and HRA Pharma. J.F. served as a consultant for Novartis and Corcept Therapeutics. M.F. has received research grants from Novartis and Corcept Therapeutics and has been a consultant for and received honoraria from Novartis and Ipsen. A.B.A. has been an investigator and a consultant for Novartis. J.S. has received consulting fees from Novartis, and S.P. from Novartis, Pfizer and Ipsen. P.S. has served as a consultant for Novartis. B.M.K.B. has recently served as the investigator on studies with research grants from Novartis and Corcept Therapeutics to the Massachusetts General Hospital Neuroendocrine Unit and as a consultant to Novartis and HRA Pharma.

Ethical standards

This study was conducted according to the ethical principles of the Declaration of Helsinki and complies with the current laws of the countries in which it was performed.

Supplementary material

11102_2013_503_MOESM1_ESM.docx (32 kb)
Supplementary material (DOCX 32 kb)


  1. 1.
    Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642PubMedCrossRefGoogle Scholar
  3. 3.
    Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533PubMedCrossRefGoogle Scholar
  4. 4.
    van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR (2007) Cushing’s syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 65:137–141PubMedGoogle Scholar
  5. 5.
    Toogood AA, Stewart PM (2008) Hypopituitarism: clinical features, diagnosis, and management. Endocrinol Metab Clin North Am 37:235–261PubMedCrossRefGoogle Scholar
  6. 6.
    Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Novartis Pharmaceuticals (2012) Signifor prescribing information. Available at: http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/signifor.pdf. Last accessed Feb 2013
  8. 8.
    Corcept Therapeutics (2012) Korlym prescribing information. Available at: http://www.corcept.com/prescribinginfo.pdf. Last accessed Feb 2013
  9. 9.
    Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707–716PubMedCrossRefGoogle Scholar
  10. 10.
    Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47PubMedCrossRefGoogle Scholar
  11. 11.
    Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary dependent Cushing’s disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115–122PubMedCrossRefGoogle Scholar
  12. 12.
    National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
  13. 13.
    Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BMK (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366:914–924PubMedCrossRefGoogle Scholar
  14. 14.
    Libe R, Groussin L, Bertherat J (2012) Pasireotide in Cushing’s disease. N Engl J Med 366:2134–2135PubMedCrossRefGoogle Scholar
  15. 15.
    Pivonello R, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, on behalf of the Pasireotide B2305 Study Group (2011) Improvement in clinical signs and symptoms of Cushing’s disease following 12 months’ pasireotide therapy. Endocrine Abstracts 26:abst P284Google Scholar
  16. 16.
    Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098PubMedCrossRefGoogle Scholar
  17. 17.
    Mercado M, Borges F, Bouterfa H, Chang T-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859–868CrossRefGoogle Scholar
  18. 18.
    Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13:18–28PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A (2010) Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):77–81PubMedCrossRefGoogle Scholar
  20. 20.
    Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167:311–326PubMedCrossRefGoogle Scholar
  21. 21.
    Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2013) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. doi:10.1007/s11102-013-0483-3 [Epub ahead of print]

Copyright information

© The Author(s) 2013

Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • M. Boscaro
    • 1
  • J. Bertherat
    • 2
    • 3
    • 4
  • J. Findling
    • 5
  • M. Fleseriu
    • 6
  • A. B. Atkinson
    • 7
  • S. Petersenn
    • 8
  • J. Schopohl
    • 9
  • P. Snyder
    • 10
  • G. Hughes
    • 11
  • A. Trovato
    • 12
  • K. Hu
    • 13
  • M. Maldonado
    • 11
  • B. M. K. Biller
    • 14
  1. 1.Division of EndocrinologyPolytechnic University of MarcheAnconaItaly
  2. 2.INSERM U1016Institut CochinParisFrance
  3. 3.Reference Centre for Rare Adrenal Diseases, Department of EndocrinologyAssistance Publique Hôpitaux de Paris, Hôpital CochinParisFrance
  4. 4.University Paris DescartesParisFrance
  5. 5.Division of Endocrinology, Metabolism, and Clinical NutritionMedical College of WisconsinMilwaukeeUSA
  6. 6.Departments of Medicine and Neurological Surgery, Northwest Pituitary CenterOregon Health & Science UniversityPortlandUSA
  7. 7.Regional Centre for Endocrinology and DiabetesRoyal Victoria HospitalBelfastUK
  8. 8.ENDOC Center for Endocrine TumorsHamburgGermany
  9. 9.Medizinische Klinik IVLudwig-Maximilians UniversityMunichGermany
  10. 10.Penn Pituitary CenterUniversity of PennsylvaniaPhiladelphiaUSA
  11. 11.Clinical Development, Oncology Business UnitNovartis Pharma AGBaselSwitzerland
  12. 12.Clinical Development, Oncology Business UnitNovartis Pharmaceuticals CorporationFlorham ParkUSA
  13. 13.Oncology Biometrics and Data ManagementNovartis Pharmaceuticals CorporationFlorham ParkUSA
  14. 14.Neuroendocrine Clinical CenterMassachusetts General HospitalBostonUSA

Personalised recommendations